Table 1

Demographic and baseline clinical characteristics of the subjects

Gla at 1000–2200 haGla at 2200–1000 haP value
N = 10b,cN = 5N = 5
Sex
 Male734
 Female321
Age (years)61.6 ± 4.562.2 ± 3.460.8 ± 4.10.573
BMI (kg/m2)28.0 ± 3.628.5 ± 4.327.5 ± 4.00.713
Known diabetes duration (years)16.5 ± 8.016.4 ± 3.216.6 ± 11.50.971
A1C0.801
 %7.2 ± 0.67.1 ± 0.57.2 ± 0.7
 mmol/mol55 ± 8.154 ± 7.955 ± 9.0
Daily insulin dose (units/kg)c
 Total0.53 ± 0.310.46 ± 0.290.60 ± 0.340.503
 Basal0.28 ± 0.110.27 ± 0.120.30 ± 0.120.703
  • Data are mean ± SD, unless otherwise indicated.

  • a Subjects split by sequence of treatments.

  • b All 10 subjects were receiving basal insulin glargine, 7 on basal bolus (glargine plus prandial rapid-acting analog); 8 subjects were also receiving oral agents (metformin, 5 subjects on basal bolus and 2 subjects receiving a basal insulin regimen; 1 subject was receiving a basal insulin regimen plus 1 mg glimepiride).

  • c Prandial (if any, rapid-acting insulin analog) plus basal (glargine insulin) regimen.